Unit:
Faculty of MedicineLibrary of the School of Health Sciences
Author:
Deligiannis Dimitrios
Dissertation committee:
Ιωάννης Αναστασίου, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Διονύσιος Μητρόπουλος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Χρήστος Αλαμανής, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Σταμάτιος Θεοχάρης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Μιχαήλ Χρυσοφός, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Στραβοδήμος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ιωάννης Αδαμάκης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Κλινική σημασία της έκφρασης των υποδοχέων κανναβινοειδών CB-1 και CB-2 σε κακοήθη νεοπλάσματα νεφρού
Translated title:
Clinical importance of the expression of the cannabinoids' receptors CB-1 and CB-2 in renal cell carcinomas
Summary:
Introduction: In recent years there has been increasing discussion about the
effect of cannabinoids on various forms of malignancy. Although it is proven,
through laboratory studies, that cannabinoids play a role in malignancies such
as breast cancer, prostate cancer and adenocarcinoma of the pancreas, there
is insufficient research data on renal cell carcinoma.
Aim: Evaluation of the expression of the cannabinoid CB1 (CB1R) and CB2
(CB2R) receptors (positivity, intensity, %, site of distribution,
Immunohistochemical score) in renal cell carcinomas and their correlation with
various clinicopathological aspects.
Materials-Methods: We retrospectively obtained data and specimens from 87
patients diagnosed with renal cell carcinoma (RCC) after partial or radical
nephrectomy and the CB1R and CB2R expression was assessed
immunohistochemically on paraffin-embedded tissues. The results were
statistically analyzed uni- and multi-factorial along with clinicopathological
parameters.
Results: CB1R was not expressed at all and the CB2R was highly expressed
in n=78 (89.7%) patients with RCC. In Unifactorial analysis, no statistical
significance was found in none of the analyzed parameters. However, in the
multifactorial analysis, we found that patients with papillary histologic type
(p<0.0005) were associated with lower likelihood of expression of the CB2R in
the membranous compared with those with clear-cell and were also associated
with higher likelihood of moderate or strong expression of CB2R
Immunohistochemical score compared with those with clear-cell (p=0.03).
Patients with Stage T2 (p=0.010) had more enhanced expression (grade 3
CB2R intensity) compared with those with Stage T1. Males (Beta coefficient ±
SE: 13.70±7.04; p=0.056) and patients with chromophobe histological type
(Beta coefficient ± SE: 23.45±9.86;p=0.020) were associated with higher
percentage of CB2R.
Conclusions: Our data suggest that CB2R, after well-designed studies,
especially the CB2R could be used as a prognostic marker or even as a
potential therapeutic target in RCC.
Main subject category:
Health Sciences
Keywords:
Renal cancer prognosis, Cannabinoid receptors, Carcinomas renal cell, CB2 receptor, CB1 receptor
Number of references:
105
